223 related articles for article (PubMed ID: 31609741)
1. Angiogenesis inhibition in non-small cell lung cancer: a critical appraisal, basic concepts and updates from American Society for Clinical Oncology 2019.
Cantelmo AR; Dejos C; Kocher F; Hilbe W; Wolf D; Pircher A
Curr Opin Oncol; 2020 Jan; 32(1):44-53. PubMed ID: 31609741
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?
Aggarwal C; Somaiah N; Simon G
Cancer Biol Ther; 2012 Mar; 13(5):247-63. PubMed ID: 22481432
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapies in non-small-cell lung cancer.
Alshangiti A; Chandhoke G; Ellis PM
Curr Oncol; 2018 Jun; 25(Suppl 1):S45-S58. PubMed ID: 29910647
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic therapy in nonsmall cell lung cancer.
Gutierrez M; Giaccone G
Curr Opin Oncol; 2008 Mar; 20(2):176-82. PubMed ID: 18300767
[TBL] [Abstract][Full Text] [Related]
5. Emerging antiangiogenic therapies for non-small-cell lung cancer.
Blakely C; Jahan T
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1607-18. PubMed ID: 21999134
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting.
Reck M; Garassino MC; Imbimbo M; Shepherd FA; Socinski MA; Shih JY; Tsao A; Lee P; Winfree KB; Sashegyi A; Cheng R; Varea R; Levy B; Garon E
Lung Cancer; 2018 Jun; 120():62-69. PubMed ID: 29748017
[TBL] [Abstract][Full Text] [Related]
7. Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC).
Schmid-Bindert G
Target Oncol; 2013 Mar; 8(1):15-26. PubMed ID: 23371029
[TBL] [Abstract][Full Text] [Related]
8. [III. Role of Anti-Angiogenesis Therapy for Advanced Non-Small Cell Lung Cancer - Current Status and Future Challenges].
Hirai F
Gan To Kagaku Ryoho; 2015 Aug; 42(8):940-3. PubMed ID: 26353391
[No Abstract] [Full Text] [Related]
9. New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer.
Qiang H; Chang Q; Xu J; Qian J; Zhang Y; Lei Y; Han B; Chu T
J Cancer Res Clin Oncol; 2020 Mar; 146(3):631-645. PubMed ID: 32065262
[TBL] [Abstract][Full Text] [Related]
10. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
Janning M; Loges S
Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer.
Rossi A; Maione P; Ferrara ML; Sacco PC; Schettino C; Bareschino MA; Gridelli C
Curr Med Chem; 2009; 16(30):3919-30. PubMed ID: 19747132
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis inhibition in the treatment of lung cancer.
Vokes E; Herbst R; Sandler A
Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy.
Rossi A; Maione P; Sacco PC; Ambrosio R; Falanga M; Gridelli C
Curr Drug Targets; 2010 Jul; 11(7):865-8784. PubMed ID: 20412044
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.
Ulahannan SV; Brahmer JR
Cancer Invest; 2011 May; 29(4):325-37. PubMed ID: 21469981
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic agents in the treatment of nonsmall cell lung cancer: reality and hope.
Ramalingam SS; Belani CP
Curr Opin Oncol; 2010 Mar; 22(2):79-85. PubMed ID: 20009926
[TBL] [Abstract][Full Text] [Related]
16. [Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].
Marco S; Tomasini P; Greillier L; Barlesi F
Rev Mal Respir; 2011 Dec; 28(10):1216-29. PubMed ID: 22152931
[TBL] [Abstract][Full Text] [Related]
17. Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer.
Aftab BT; Dobromilskaya I; Liu JO; Rudin CM
Cancer Res; 2011 Nov; 71(21):6764-72. PubMed ID: 21896639
[TBL] [Abstract][Full Text] [Related]
18. Incorporation of Antiangiogenic Therapy Into the Non-Small-Cell Lung Cancer Paradigm.
Chu BF; Otterson GA
Clin Lung Cancer; 2016 Nov; 17(6):493-506. PubMed ID: 27381269
[TBL] [Abstract][Full Text] [Related]
19. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.
Manegold C; Dingemans AC; Gray JE; Nakagawa K; Nicolson M; Peters S; Reck M; Wu YL; Brustugun OT; Crinò L; Felip E; Fennell D; Garrido P; Huber RM; Marabelle A; Moniuszko M; Mornex F; Novello S; Papotti M; Pérol M; Smit EF; Syrigos K; van Meerbeeck JP; van Zandwijk N; Yang JC; Zhou C; Vokes E
J Thorac Oncol; 2017 Feb; 12(2):194-207. PubMed ID: 27729297
[TBL] [Abstract][Full Text] [Related]
20. Targeting tumor neovasculature in non-small-cell lung cancer.
Pallis AG; Syrigos KN
Crit Rev Oncol Hematol; 2013 May; 86(2):130-42. PubMed ID: 23159217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]